Diabetes epidemiology and management最新文献

{"title":"Erratum regarding previously published articles","authors":"","doi":"10.1016/j.deman.2026.100311","DOIUrl":"10.1016/j.deman.2026.100311","url":null,"abstract":"","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100311"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147612126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of diabetes self-management education and support on long-term glycemic control","authors":"Benjamin Lalani ,&nbsp;Nisa M. Maruthur ,&nbsp;Eugene Arnold ,&nbsp;Scott A. Berkowitz ,&nbsp;Jason Fu ,&nbsp;Dingfen Han ,&nbsp;Caitlin Nass ,&nbsp;Sudipa Sarkar ,&nbsp;Nae-Yuh Wang ,&nbsp;Hsin-Chieh Yeh ,&nbsp;Mohammed Abusamaan ,&nbsp;Nestoras N. Mathioudakis","doi":"10.1016/j.deman.2026.100312","DOIUrl":"10.1016/j.deman.2026.100312","url":null,"abstract":"<div><div>In this retrospective cohort study of 13,087 patients, those who participated in diabetes self-management education and support (DSMES) experienced a 1.03% (11 mmol/mol) adjusted decline in HbA1c over 24 months, which was 0.19% (2 mmol/mol) greater than the adjusted reduction observed in non-participants. This supports DSMES as an effective intervention.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100312"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147709406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enriching administrative data to extend real-world knowledge of diabetes: design of the French national diabetes survey Entred 3","authors":"Clara Piffaretti,&nbsp;Leila Saboni,&nbsp;Laetitia Bénézet,&nbsp;Laurence Mandereau-Bruno,&nbsp;Céline Lavalette,&nbsp;Jean-Michel Race,&nbsp;Camille Thomassin,&nbsp;Antoine Rachas,&nbsp;Sandrine Fosse-Edorh","doi":"10.1016/j.deman.2026.100325","DOIUrl":"10.1016/j.deman.2026.100325","url":null,"abstract":"<div><h3>Aims</h3><div>The significant burden of diabetes requires reliable information collection. While administrative databases are an essential source of information, they have limitations, especially when they are relied upon as the sole data source. This article presents how enriching administrative databases with survey-based data can overcome these limitations and improve knowledge of diabetes.</div></div><div><h3>Methods</h3><div>Based on a random sample of 12,772 people living with diabetes in France, the Entred 3 study complements administrative data with self-reported and medical data, including biological test results.</div></div><div><h3>Results</h3><div>By complementing administrative data with a multi-source approach, we conducted a study on a wider range of diabetes-related topics (e.g., quality of life, health literacy, glycemic control, and individual socio-economic information) for a sample representative of the population treated pharmacologically for diabetes in France, with the data further analyzed by diabetes type. In European France, administrative data were extracted for 8,138 individuals (93.2%) and 3,166 individuals (36.3%) participated in the patient questionnaire. Of these, 1,332 of their physicians also completed a questionnaire (42.1%). Among people living with diabetes, 94.1% had type 2 diabetes, and 5.1% had type 1 diabetes.</div></div><div><h3>Conclusion</h3><div>The real-world data collected in the Entred 3 study provide essential epidemiological, medical, economic, and social information for the development and direction of prevention campaigns aimed at improving medical practices, health status, and quality of life for people living with diabetes.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100325"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148634299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gestational diabetes mellitus in sub-Saharan Africa: Diagnostic gaps, β-cell dysfunction, and opportunities for postpartum prevention of type 2 diabetes","authors":"Justin Kambale Kahingi,&nbsp;Olivier Kasanda Dibomba,&nbsp;Prisca Kalonji Munanga,&nbsp;Relindis Mpembe Ngila,&nbsp;Roland Muhindo Muyisa,&nbsp;Junior Mboloko Mata","doi":"10.1016/j.deman.2026.100336","DOIUrl":"10.1016/j.deman.2026.100336","url":null,"abstract":"<div><h3>Background</h3><div>Gestational diabetes mellitus (GDM) is an emerging public health concern in sub-Saharan Africa (SSA), occurring in the context of rapid urbanization, nutritional transition, lifestyle changes, and underlying metabolic susceptibility. GDM also provides an important opportunity to identify women at increased risk of future type 2 diabetes mellitus (T2DM), although postpartum follow-up remains inadequate.</div></div><div><h3>Methods</h3><div>A narrative review of literature published from March 2010 to June 2026 was conducted using PubMed/MEDLINE, Scopus, Embase, Cochrane Library, and Google Scholar. Evidence on GDM epidemiology, diagnostic heterogeneity, metabolic mechanisms, β-cell dysfunction, postpartum progression to T2DM, and health-system approaches to postpartum prevention was synthesized, with particular emphasis on SSA and populations of African ancestry.</div></div><div><h3>Results</h3><div>Reported GDM prevalence in SSA varies substantially according to diagnostic criteria, screening strategies, and study populations. Evidence from populations of African ancestry suggests that impaired β-cell secretory capacity may contribute importantly to dysglycaemia, including in individuals without marked obesity. Pregnancy-related metabolic stress may further expose this limited β-cell reserve. However, direct longitudinal evidence demonstrating accelerated progression from GDM to T2DM in SSA remains limited. Postpartum glucose testing and long-term follow-up are also suboptimal, resulting in missed opportunities for early identification and prevention.</div></div><div><h3>Conclusion</h3><div>The GDM-to-T2DM continuum in SSA requires greater attention to both biological susceptibility and health-system barriers. Harmonized diagnostic approaches, integrating postpartum metabolic screening into maternal and child health services, task shifting, and well-evaluated mHealth strategies may improve continuity of care and strengthen postpartum diabetes prevention.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100336"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149140850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precipitating causes of diabetic ketoacidosis in emergency department: a retrospective cohort study","authors":"Clémence Castell-Saun ,&nbsp;Cyrille Mouret ,&nbsp;Venkatesh Thiruganasambandamoorthy ,&nbsp;Xavier Dubucs ,&nbsp;Frederic Balen","doi":"10.1016/j.deman.2025.100291","DOIUrl":"10.1016/j.deman.2025.100291","url":null,"abstract":"","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100291"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145610368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Comorbidity depression – diabetes in Eastern DR Congo: insights from a cross-sectional study” [Diabetes Epidemiology and Management (2025) 100289]","authors":"Roland Muhindo Muyisa Laros,&nbsp;Jacques Katsuva Wahangire,&nbsp;Célestin Kaputu Malu","doi":"10.1016/j.deman.2026.100323","DOIUrl":"10.1016/j.deman.2026.100323","url":null,"abstract":"","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100323"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148634300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking type 2 diabetes prevention in Canada through Indigenous food sovereignty","authors":"Muhammad Saim,&nbsp;Haris Ahmad,&nbsp;Hayder Al-Kazzaz","doi":"10.1016/j.deman.2026.100330","DOIUrl":"10.1016/j.deman.2026.100330","url":null,"abstract":"","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100330"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148730310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Population-level impact of cross-wave glycaemic marker comparability on estimated diabetes incidence: a CHARLS sensitivity analysis","authors":"Beibei Huang,&nbsp;Hang Xu","doi":"10.1016/j.deman.2026.100334","DOIUrl":"10.1016/j.deman.2026.100334","url":null,"abstract":"<div><h3>Background</h3><div>Longitudinal surveys may apply fixed glycaemic thresholds across waves despite changes in laboratory methods. We quantified the sensitivity of estimated four-year diabetes incidence to alternative assumptions about cross-wave comparability of HbA1c and glucose in the China Health and Retirement Longitudinal Study.</div></div><div><h3>Methods</h3><div>Among 10,041 eligible baseline participants without diabetes, 6493 entered the paired analytic cohort. We compared observed definitions with scenarios that mapped 2015 HbA1c, glucose, or both markers to the 2011 scale. The HbA1c-independent definition relied on diagnosis, medication use, and one unconfirmed glucose measurement. Primary estimates used 2011 blood-sample weights, and a response-weighted analysis addressed selection into repeat biomarker measurement. Confidence intervals used 2000 community-cluster bootstrap replicates with all relevant mapping parameters re-estimated per replicate.</div></div><div><h3>Results</h3><div>The observed HbA1c-inclusive definition yielded 10.11% incidence (95% CI 8.41–12.28), compared with 4.26% (3.58–4.94) for the HbA1c-independent definition. Estimates were 4.45%-4.58% after HbA1c-only mapping, 4.27%-4.52% after overall glucose-only mapping, 5.66%-5.67% after fasting-stratified glucose-only mapping, and 5.79%-5.90% after joint mapping. Response-weighted estimates were similar. Among 7433 participants with both markers at both waves, 61.6% had higher HbA1c but lower glucose in 2015. This discordance was compatible with a cross-wave shift in either or both markers.</div></div><div><h3>Conclusions</h3><div>Estimated incidence varied materially across assumptions about cross-wave HbA1c and glucose comparability. Observed definitions and mapping scenarios yielded divergent estimates, while the true incidence and relative contributions of HbA1c and glucose remained uncertain. Longitudinal diabetes surveillance should assess each marker affected by a laboratory transition and report clearly labelled sensitivity analyses when direct calibration is unavailable.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"21 ","pages":"Article 100334"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148951047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous Glucose Monitoring (CGM) use in patients with diabetes mellitus type 1 is associated with higher healthcare costs, increased hospitalizations, and social disparities in a real-world setting: Analysis of adoption pattern, impact on health services utilization and cost of care in a large integrated health system","authors":"Ameer Khowaja ,&nbsp;Lina Adil ,&nbsp;Teigan Dwyer ,&nbsp;Tyson Barrett ,&nbsp;Jamil Alkhaddo","doi":"10.1016/j.deman.2025.100274","DOIUrl":"10.1016/j.deman.2025.100274","url":null,"abstract":"<div><h3>Background</h3><div>With the rising prevalence of diabetes mellitus type 1 (DM type 1), continuous glucose monitoring (CGM) has emerged as a key management tool. While studies suggest CGM improves glycemic control, its broader impact on healthcare utilization and costs remains limited. This study evaluates demographic and clinical variations between DM type 1 patients using CGM and non-CGM users; assessing healthcare utilization, glycemic outcomes, costs and impact on Durable Medical Equipment (DME).</div></div><div><h3>Methods</h3><div>A retrospective cohort analysis was conducted using health insurance claims and electronic medical records from Allegheny Health Network (AHN) from 2019 to 2021. Patient eligibility required 36 months of continuous medical and drug coverage; insulin use and AHN affiliation. The cohort included 3007 patients, divided into CGM users and non-users. Additionally, patient data was stratified by demographics, social vulnerability index (SVI), healthcare use by per member per month (PMPM) and 1000 person-months.</div></div><div><h3>Results</h3><div>CGM users had higher PMPM and utilization/1000 for all service types, except for DME, when compared to non-CGM users. There was a progressive increase in the cost of prescriptions among CGM users (prescription PMPM, 2019: $621.33, 2020: $723.97, 2021: $851.39). Non-CGM users had greater prescription-related expenses, comprising 43 % of total costs but a higher likelihood of achieving an HbA1c &lt;9.0. Number of hospitalizations was significantly higher among CGM users compared to non-CGM users (18.4 % vs. 10.55 %, <em>p</em> &lt; 0.001). CGM use was more common among non-Caucasian, non-English-speaking, and tobacco-using groups but declined with increasing SVI. CGM users had higher rates of frailty, depression, congestive heart failure and seizures.</div></div><div><h3>Conclusion</h3><div>This study highlights the complexity of CGM uptake and its impact on healthcare costs in DM type 1 patients. Increased healthcare spending associated with CGM use raises concerns about cost-effectiveness and accessibility. Further studies are needed to assess disparities in CGM utilization and diabetes management including diabetes-related complications and associated costs across varying demographics and socioeconomic groups.</div></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"19 ","pages":"Article 100274"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144672106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes medications and dementia risk: Comparisons of SGLT2 inhibitors, GLP-1 RAs, metformin, and their combinations","authors":"Gabrielle R. Nemeh ,&nbsp;Aubrey L. Doede ,&nbsp;Raphael E. Cuomo","doi":"10.1016/j.deman.2025.100288","DOIUrl":"10.1016/j.deman.2025.100288","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Type 2 diabetes (T2D) elevates dementia risk through vascular injury, neuroinflammation, and perturbed insulin signaling. Antidiabetic classes differ in extra-glycemic actions that could modify neurodegeneration, yet head-to-head comparative data remain limited.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To compare time to incident dementia among older adults with T2D exposed to SGLT2 inhibitors, GLP-1 receptor agonists (GLP-1 RAs), metformin, or two-way combinations, and to quantify the contribution of comorbidities and neuroactive co-medications.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;We performed a retrospective cohort study in the UCHDW (2012–2024). Adults aged 55–80 were assigned to the earliest qualifying exposure group and followed from index to first coded Alzheimer’s disease or unspecified dementia; vascular/multi-infarct dementias were excluded by design to reduce etiologic heterogeneity. Events recorded within 84 days of index were not considered incident outcomes (individuals were retained and censored at 84 days). Covariates included age, sex, cardiovascular disease, hypertension, chronic kidney disease, obesity, smoking, anticholinergic/overactive bladder agents, tricyclic antidepressants, proton-pump inhibitors, opioids, benzodiazepines, and ever-exposure to insulin, DPP-4 inhibitors, sulfonylureas, and thiazolidinediones. Analyses comprised Kaplan–Meier (KM) curves with log-rank testing, a pooled multivariable Cox model with a six-level exposure factor, and one-versus-rest Cox models complemented by stabilized, truncated inverse probability of treatment weighting (IPTW).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The cohort included 22,677 SGLT2-only (150 events; 0.66 %), 219,523 metformin-only (2,174; 0.99 %), 35,012 GLP-1-only (149; 0.43 %), 37,317 SGLT2+metformin (453; 1.21 %), 7,210 SGLT2+GLP-1 (62; 0.86 %), and 41,595 metformin+GLP-1 (421; 1.01 %). KM curves differed significantly (log-rank χ²=38.5, p&lt;0.001). In the pooled Cox model (reference SGLT2-only), metformin-only (HR=1.24, 95 % CI 1.05–1.47; p=0.011) and SGLT2+metformin (HR=1.21, 95 % CI 1.00–1.46; p=0.045) had higher hazards; GLP-1-only (HR=0.94, 95 % CI 0.74–1.20; p=0.614) and SGLT2+GLP-1 (HR=0.85, 95 % CI 0.64–1.15; p=0.299) did not differ significantly; metformin+GLP-1 trended higher (HR=1.18, 95 % CI 0.97–1.42; p=0.092). Absolute risk differences were small (0.23–0.78 percentage points vs GLP-1-only). One-versus-rest models yielded directionally consistent estimates; IPTW with 1st–99th percentile truncation improved covariate balance and produced stable weighted estimates. Median follow-up (years) was 1.96 (SGLT2-only), 5.34 (metformin-only), 1.81 (GLP-1-only), 4.13 (SGLT2+metformin), 3.44 (SGLT2+GLP-1), and 4.84 (metformin+GLP-1).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;In routine care of older adults with T2D, GLP-1 RA monotherapy demonstrates the most favorable dementia profile, whereas metformin monotherapy and SGLT2+metformin identify gr","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"19 ","pages":"Article 100288"},"PeriodicalIF":1.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145465336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}